Three Pharma Campaign Types That Should Already Be Running on Your Clinical Screens

Pharma has never stopped believing in point-of-care. The waiting room, the exam room, the moment before a physician walk in - these are not just high-attention environments. They are, in theory, the most contextually valuable real estate in healthcare marketing.

Because the version of in-clinic media most networks have been selling isn't delivering on that premise. It's delivering rotation. It's delivering impressions distributed across whoever happens to be sitting in a waiting room at a given time - a mix of patients that has nothing to do with your campaign objectives. You're paying for context you're not actually getting.

That's the gap. And it matters more now than it ever has, because the campaigns pharma is building today are not general awareness plays. They are designed around specific patient moments. And those moments require infrastructure that most clinical screens were never built to support.

Here's where it's breaking down - and what it means for the three campaign types your teams are almost certainly planning right now.

1. Chronic Disease Awareness: The Diagnosis Window Is Narrow. Your Messaging Isn't.

The strategic intent is clear: reach patients at or near the moment of diagnosis, when disease education lands differently and shapes how they enter the treatment conversation with their physician.

The execution reality: your messaging is rotating through a general population. Some of those patients are newly diagnosed. Most are not. And there is no mechanism distinguishing between them.

The result is diluted impact dressed up as point-of-care. The environment is right. The targeting isn't.

What makes chronic disease awareness work at this stage is visit-signal alignment - knowing not just that a patient is in clinic, but why. When a check-in reflects a relevant diagnosis context, messaging should respond to it in real time. Not later, not probabilistically - immediately, while the patient is preparing to have exactly the conversation your campaign is designed to support.

Without that, you're not running a precision campaign. You're running a poster.

2. New Treatment Launches: Influence Happens in a Window. You May Be Missing It.

Launch budgets carry expectations that general inventory can't meet. When a brand introduces a new therapy, the goal isn't visibility among a broad clinical audience. It's influence during the treatment consideration window - when a physician is evaluating options, when a patient is open to asking questions they haven't asked before.

That window is real. It's also brief. And it requires that your messaging reach patients whose visit context actually reflects active treatment evaluation.

What most networks offer instead is probabilistic reach - messaging delivered widely in the hope that a relevant subset of viewers receive it. That's not a launch strategy. That's media buying from 2015 applied to a 2025 brief.

Launch campaigns deserve inventory that responds to patient profiles and visit context in real time. When the right criteria are met, the message appears. When they're not, it doesn't. That's not a complicated ask. It's the baseline expectation digital channels have been meeting for years. In-clinic media needs to catch up.

3. Adherence and Persistence: Your Most Valuable Patient Is Already On Therapy. Are You Reaching Them?

Adherence investment often gets treated as secondary to acquisition, but in many therapeutic areas, long-term persistence is where the real value lives. Patients who stay on therapy, who understand their condition, who come in for follow-up - these are the patients that sustained investment is designed to support.

And yet adherence campaigns are routinely served to mixed audiences that include patients who have never been on the relevant therapy, don't have the relevant condition, and have no business seeing the message.

That's not a minor inefficiency. It's a credibility problem. Messaging designed to reinforce a treatment journey lands differently - and often worse - when it reaches the wrong audience. It signals to everyone that the channel can't actually distinguish who's seeing what.

Effective adherence campaigns require patient-profile targeting and journey-stage awareness. They need to reach patients who are actively managing a condition, during follow-up or management visits, when continuity is already on their mind. That kind of precision is achievable in clinical environments. It's just not achievable on networks running undifferentiated rotations.

The Common Thread

Three different campaign types. Three different strategic objectives. One shared problem: in-clinic media that can't connect messaging to the patient context it was built around.

Pharma teams know this. The frustration isn't new. What's new is that the infrastructure to fix it now exists - a real-time decisioning infrastructure that evaluates check-in signals against live campaign criteria and delivers contextually aligned messaging instantly, within existing screen environments, without hardware changes or disruption to network operations.

The technology is called Spark For DOOH, powered by Doceree. It works through a simple API integration. It handles HIPAA-compliant data throughout. And it turns the screens that were already in the right place into inventory that finally delivers on the promise in-clinic media has always made.

Pharma isn't struggling to spend on point-of-care. It's struggling to find networks that can actually execute the campaigns being planned.

The gap is closeable. The question is which networks close it first - and whether your next campaign brief goes to one of them. 

To explore more, visit us at: Spark DOOH